Quebec Expands Patient Access to Chronic Hepatitis C Therapies

Gilead applauds Quebec's Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness Quebec's expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes Gilead's new product, VOSEVI™ is now available on the List of Medications The removal of the fibrosis level criterion for access furthers Canada's co...

The Week in Review: March 2 – March 9, 2018

Friday, March 9, 2018 News Recap: Canada: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 – March 12 – 21, 2018. We are happy to announce that a 10-day roadtrip to northern Vancouver Island is just around the corner! We will be bringing hot-off-the-press posters, pamphlets, and audio-visual resources to community organizations and Friendship Centres, band health centres, and health clinics. See links to some of the resources we...

Ontario: Provincial funding for hepatitis C drugs a game changer, health professionals say

Changes spurred by development of minimally invasive drugs with extremely high cure rates. Health professionals are voicing excitement about new changes regarding the availability of hepatitis C treatment under Ontario's Drug Benefit program. The Ontario government says it will cover the cost of medication for all hepatitis C patients, regardless of the severity of the disease, a move that's being touted as a game-changing decision by health professionals

The Week in Review: February 23 – March 2, 2018

Friday, March 2, 2018 News Recap: Canada: Shifting from concern to crisis: 1 in 4 Canadians may be affected by liver disease. Recent indicators gathered by the Canadian Liver Foundation (CLF) show that an increased prevalence of liver diseases including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B & C, and liver cancer are why in just ten years, the statistic that was once 1 in 10, is now 1 in 4. Ontario Expands Patient Acce...

U.S.: New York Insurers to Change Coverage of Hepatitis C Drugs

Deal requires seven insurers to cover the drugs for most patients with commercial insurance plans Seven health-insurance companies in New York will change their criteria for covering costly drugs that cure chronic hepatitis C under the terms of agreements with the office of State Attorney General Eric Schneiderman. The agreements, announced Tuesday, require the insurers to cover hepatitis C medications for nearly all patients who have commercial insura